Table 1.
Description of baseline survey data. The study sites are given with the baseline sample size and microfilariae (mf) prevalence (%), blood volumes collected during the survey to test for mf positivity, annual biting rate (ABR) of vector mosquitoes, dominant vector species and drug regimen used for simulating the chemotherapeutic interventions by mass drug administration (MDA) without/with vector control (VC)
| Study villages | Mf Sample size | Blood volume (μl) |
cMf (%) | dBaseline ABR | CFA sample size | CFA (%) | Mosquito species (genus) | aDrug regimen | bDrug’s efficacies (ω, ε, TP) | Source |
|---|---|---|---|---|---|---|---|---|---|---|
| Peneng | 63 | 1000 | 66.67 | 8194 | - | - | An. | DEC + ALB | (55, 95, 6) | [10, 18, 78, 79] |
| Albulum | 50 | 1000 | 80 | 42328 | - | - | An. | DEC + ALB | (55, 95, 6) | [10, 18, 78, 79] |
| Yauatong | 131 | 1000 | 92.37 | 37052 | - | - | An. | DEC + ALB | (55, 95, 6) | [10, 18, 78, 79] |
| Nanaha | 211 | 1000 | 54.98 | 11611 | - | - | An. | DEC + ALB | (55, 95, 6) | [10, 18, 78, 79] |
| Ngahmbule | 346 | 1000 | 51.16 | 4346 | - | - | An. | DEC + ALB | (55, 95, 6) | [10, 18, 78, 79] |
| Tawalani | 367 | 100 | 35.72 | 12850 | - | - | An. | IVM + ALB | (35, 99, 9) | [80] |
| eJaribuni | 1007 | 100 | 25.35 | 15677 | - | - | An. | IVM + ALB | (35, 99, 9) | [81, 82] |
| Tingrela | 699 | 20 | 63.89 | 4156 | - | - | An. | IVM + ALB | (35, 99, 9) | [83] |
| Chiconi | 245 | 20 | 58.90 | 10586 | - | - | An. | IVM + ALB | (35, 99, 9) | [84] |
| eMasaika | 848 | 100 | 28.61 | 6184 | 837 | 52.2 | An. | IVM + ALB | (35, 99, 9) | [85] |
| eKirare | 919 | 100 | 28.18 | 2090 | 90 | 53.3 | An. | IVM + ALB | (35, 99, 9) | [86] |
| eAlebtong | 739 | 100 | 33.47 | 58292 | 890 | 29.1 | An. | IVM + ALB | (35, 99, 9) | [87] |
| eLwala | 572 | 100 | 21.05 | 16341 | 896 | 18.3 | An. | IVM + ALB | (35, 99, 9) | [87] |
| eObalanga | 799 | 100 | 34.62 | 4587 | 900 | 30.1 | An. | IVM + ALB | (35, 99, 9) | [87] |
| eKingwede | 825 | 100 | 3.07 | 1548 | - | - | Cx. | IVM + ALB | (35, 99, 9) | [85] |
| eMao | 546 | 100 | 27.8 | 25439 | - | - | Cx. | IVM + ALB | (35, 99, 9) | [80] |
| eMambrui | 787 | 100 | 24.99 | 4964 | - | - | Cx. | IVM + ALB | (35, 99, 9) | [81, 82] |
| Pondicherry | 1549 | 20 | 34.74 | 88500 | - | - | Cx. | DEC + ALB | (55, 95, 6) | [88] |
| Calcutta | 861 | 20 | 26.72 | 115942 | - | - | Cx. | DEC + ALB | (55, 95, 6) | [89, 90] |
| Vettavallam | 7976 | 20 | 22.83 | 100375 | - | - | Cx. | DEC + ALB | (55, 95, 6) | [91] |
| Pakistan | 1443 | 20 | 31.49 | 1607 | - | - | Cx. | DEC + ALB | (55, 95, 6) | [92, 93] |
| Jakarta | 922 | 20 | 12.27 | 223000 | - | - | Cx. | DEC + ALB | (55, 95, 6) | [94] |
An.: Anopheles mosquitoes; Cx.: Culex mosquitoes; Drug’s efficacies (ω,ε, T P): (instantaneous kill rate (%) for adult worms, instantaneous kill rate (%) for mf, drug’s efficacy period in months); mf (%): mf prevalence in percentages calculated from the number of mf-positive samples out of the total individuals sampled (sample size) in a study site; DEC: diethylcarbamazine citrate; IVM: Ivermectin; ALB: Albendazole.
aThe combination drug regimens used for MDA simulations in each site areas are as recommended for each site region by the WHO [95, 96].
bDrug efficacy values are taken from [3].
cAll mf prevalence values were standardized to reflect sampling of 1 ml blood volumes using a transformation factor of 1.95 and 1.15 respectively for values originally estimated using 20 or 100 μl blood volumes [49].
dBaseline ABR are used to obtain the monthly biting rate (MBR = ABR/12), which is used as inputs into the LF models described in the text. The symbol (−) indicates that the baseline CFA data are either not available or available but not broken by age-groups.
eThese sites have mixed vector species: here they are represented by the dominant vector species.